- Oops!Something went wrong.Please try again later.
The company said an independent Data Safety Monitoring Board found no safety concerns for the vaccine, dubbed CV2CoV.
“The trial will continue to collect sufficient data in order to conduct statistically significant efficacy analysis,” the company said in its statement.
In its Q1 earnings release, the company said CV2CoV data readout from the pivotal Phase 2b/3 trial is expected in June 2021.
Price Action: CVAC shares are down 3.5% at $107.56 during the market session on the last check Tuesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.